TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
Cytiva BioProcess R&D AB
Closing information (x1000 NOK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
13,494,200
|
12,954,256
|
16,091,605 |
| Financial expenses |
3,958
|
0
|
10,919 |
| Earnings before taxes |
4,195,725
|
6,100,224
|
9,366,376 |
| EBITDA |
12,903,332
|
12,424,053
|
15,593,914 |
| Total assets |
25,649,827
|
37,427,767
|
33,495,515 |
| Current assets |
9,653,233
|
15,129,988
|
12,459,577 |
| Current liabilities |
12,818,101
|
14,425,652
|
21,641,178 |
| Equity capital |
12,831,726
|
23,002,115
|
10,910,163 |
| - share capital |
103
|
101
|
95 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
50.0%
|
61.5%
|
32.6% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
31.1%
|
47.1%
|
58.2% |
| Return on assets (ROA) |
16.4%
|
16.3%
|
28.0% |
| Current ratio |
75.3%
|
104.9%
|
57.6% |
| Return on equity (ROE) |
32.7%
|
26.5%
|
85.9% |
| Change turnover |
306,368
|
-4,279,160
|
2,105,069 |
| Change turnover % |
2%
|
-25%
|
15% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.